We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Approved for AD patients who are candidates for systemic therapy, Dupixent is the first targeted biologic in the European Union to receive authorisation for the chronic inflammatory disease.